- Home
- GNFT vs IPHA Comparison
GNFT vs IPHA Comparison
Compare GNFT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- IPHA
- Stock Information
- Founded
- GNFT 1999
- IPHA 1999
- Country
- GNFT France
- IPHA France
- Employees
- GNFT N/A
- IPHA N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- IPHA Health Care
- Exchange
- GNFT Nasdaq
- IPHA Nasdaq
- Market Cap
- GNFT 172.2M
- IPHA 148.3M
- IPO Year
- GNFT 2019
- IPHA 2019
- Fundamental
- Price
- GNFT $3.47
- IPHA $1.69
- Analyst Decision
- GNFT Strong Buy
- IPHA Strong Buy
- Analyst Count
- GNFT 1
- IPHA 1
- Target Price
- GNFT $13.00
- IPHA $11.50
- AVG Volume (30 Days)
- GNFT 6.9K
- IPHA 49.9K
- Earning Date
- GNFT 09-19-2024
- IPHA 09-12-2024
- Dividend Yield
- GNFT N/A
- IPHA N/A
- EPS Growth
- GNFT N/A
- IPHA N/A
- EPS
- GNFT 0.47
- IPHA N/A
- Revenue
- GNFT $86,225,222.00
- IPHA $36,202,722.00
- Revenue This Year
- GNFT $145.20
- IPHA N/A
- Revenue Next Year
- GNFT N/A
- IPHA $101.65
- P/E Ratio
- GNFT $7.23
- IPHA N/A
- Revenue Growth
- GNFT 175.45
- IPHA N/A
- 52 Week Low
- GNFT $3.33
- IPHA $1.29
- 52 Week High
- GNFT $6.42
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- GNFT 31.89
- IPHA 42.95
- Support Level
- GNFT $3.35
- IPHA $1.60
- Resistance Level
- GNFT $3.57
- IPHA $1.87
- Average True Range (ATR)
- GNFT 0.11
- IPHA 0.13
- MACD
- GNFT 0.01
- IPHA -0.04
- Stochastic Oscillator
- GNFT 21.82
- IPHA 16.67
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.